Description General description A cell-permeable imidazolium derivative that suppresses survivin expression, blocks survivin promoter activity, and induces apoptosis in a variety of tumor cell lines (IC50 = 540nM) in a dose-dependent manner. The main target of YM155 appears to be the interleukin enhancer-binding factor 3 (ILF3/NF110) with shorter C-terminal lengths associated with reduced binding. Exhibits potent anti-tumor effects without any severe systemic toxicity in murine models. Reported to induce tumor regression by suppressing intratumor survivin levels in PC3-xenograph tumor models (by 47% and 80% at 1 and 5 mg/kg, respectively. Packaging 10 mg in Glass bottle Biochem/physiol Actions Cell permeable: yes Primary Target Interleukin enhancer-binding factor 3 (ILF3/NF110) Reversible: yes Secondary Target Unknown Packaging Packaged under inert gas Warning Toxicity: Standard Handling (A) Reconstitution Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C. Other Notes Nakamura, N., et al. 2012. Mol. Cell. Proteomics.11, M111.0132434. Tolcher, A.W., et al. 2008, J. Clin. Oncol.26, 5198. Nakahara, T., et al. 2007, Cancer Res.67, 8014.